Antitumor Activity of the Novel BTK Inhibitor TG-1701 Is Associated with Disruption of Ikaros Signaling in Patients with B-cell Non–Hodgkin Lymphoma-Reference-Cited by-同舟云学术

Antitumor Activity of the Novel BTK Inhibitor TG-1701 Is Associated with Disruption of Ikaros Signaling in Patients with B-cell Non–Hodgkin Lymphoma

Published:2021-09-22 Issue:23 Volume:27 Page:6591-6601
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Ribeiro Marcelo Lima,Reyes-Garau Diana,Vinyoles Meritxell,Profitós Pelejà Núria^ORCID,Santos Juliana Carvalho,Armengol Marc,Fernández-Serrano Miranda^ORCID,Sedó Mor Alícia,Bech-Serra Joan J.,Blecua Pedro^ORCID,Musulen Eva^ORCID,De La Torre Carolina^ORCID,Miskin Hari,Esteller Manel^ORCID,Bosch Francesc^ORCID,Menéndez Pablo,Normant Emmanuel,Roué Gaël^ORCID

Funder

Fondo de Investigación Sanitaria

Sara Borrell research

Instituto de Salud Carlos IIIPROTEOblood

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Research of Active Compounds from Allii Macrostemonis Bulbus and Potential Targets against Non-Hodgkin’s Lymphoma Based on Network Pharmacology;Current Computer-Aided Drug Design;2024-06

2. G protein-coupled receptor 183 mediates the sensitization of Burkitt lymphoma tumors to CD47 immune checkpoint blockade by anti-CD20/PI3Kδi dual therapy;Frontiers in Immunology;2023-04-21

3. Targeting MYC-driven lymphoma: lessons learned and future directions;Cancer Drug Resistance;2023

4. BTK inhibitors in the treatment of hematological malignancies and inflammatory diseases: mechanisms and clinical studies;Journal of Hematology & Oncology;2022-10-01

5. Bruton’s Kinase Inhibitors for the Treatment of Immunological Diseases: Current Status and Perspectives;Journal of Clinical Medicine;2022-05-16